Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial

The Lancet Infectious Diseases

Volumn 18, Issue 3, 2018, Pages 296-307

  Guery, Benoit ^a   Menichetti, Francesco ^b   Anttila, Veli Jukka ^c   Adomakoh, Nicholas ^d   Aguado, Jose Maria ^e   Bisnauthsing, Karen ^f   Georgopali, Areti ^d   Goldenberg, Simon D ^f   Karas, Andreas ^d   Kazeem, Gbenga ^d   Longshaw, Chris ^d   Palacios Fabrega, Jose Alejandro ^d   Cornely, Oliver A ^g   Vehreschild, Maria J G T ^g  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b CISANELLO HOSPITAL   (Italy)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d Astellas Pharma Europe Ltd   (United Kingdom)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^g UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FIDAXOMICIN; VANCOMYCIN;

AGED; ANEMIA; ARTICLE; BILE DUCT STONE; CLINICAL OUTCOME; CLOSTRIDIUM DIFFICILE INFECTION; CLOSTRIDIUM INFECTION; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; ECZEMA; FEMALE; FEVER; HEART FAILURE; HUMAN; ILEUS; KLEBSIELLA INFECTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SEPSIS; SOMNOLENCE; TREATMENT DURATION; URINARY TRACT INFECTION; CLINICAL TRIAL; MIDDLE AGED; PEPTOCLOSTRIDIUM DIFFICILE; PSEUDOMEMBRANOUS COLITIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; FIDAXOMICIN; HUMANS; MALE; MIDDLE AGED; VANCOMYCIN;

EID: 85038895487     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(17)30751-X     Document Type: Article

References (25)

1. Bouza, E, Consequences of Clostridium difficile infection: understanding the healthcare burden. Clin Microbiol Infect 18:suppl 6 (2012), 5–12.
2. Bauer, MP, Notermans, DW, van Benthem, BH, et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 377 (2011), 63–73.
3. Debast, S, Bauer, M, Kuijper, E, European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 20 (2014), 1–26.
4. Karas, JA, Enoch, DA, Aliyu, SH, A review of mortality due to Clostridium difficile infection. J Infect 61 (2010), 1–8.
5. Aguado, JM, Anttila, VJ, Galperine, T, et al. Highlighting clinical needs in Clostridium difficile infection: the views of European healthcare professionals at the front line. J Hosp Infect 90 (2015), 117–125.
6. Heimann, SM, Vehreschild, JJ, Cornely, OA, et al. Economic burden of Clostridium difficile associated diarrhoea: a cost-of-illness study from a German tertiary care hospital. Infection 43 (2015), 707–714.
7. Mizusawa M, Doron S, Gorbach S. Clostridium difficile diarrhea in the elderly: current issues and management options. Drugs Aging 15; 32: 639–47.
8. Britton, RA, Young, VB, Interaction between the intestinal microbiota and host in Clostridium difficile colonization resistance. Trends Microbiol 20 (2012), 313–319.
9. Buffie, CG, Bucci, V, Stein, RR, et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517 (2015), 205–208.
10. Louie, TJ, Cannon, K, Byrne, B, et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis 55:suppl 2 (2012), S132–S142.
11. Isaac, S, Scher, JU, Djukovic, A, et al. Short- and long-term effects of oral vancomycin on the human intestinal microbiota. J Antimicrob Chemother 72 (2017), 128–136.
12. Cornely, OA, Crook, DW, Esposito, R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 12 (2012), 281–289.
13. Louie, TJ, Miller, MA, Mullane, K, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 364 (2011), 422–431.
14. Chilton, CH, Crowther, GS, Todhunter, SL, et al. Efficacy of alternative fidaxomicin dosing regimens for treatment of simulated Clostridium difficile infection in an in vitro human gut model. J Antimicrob Chemother 70 (2015), 2598–2607.
15. Iarikov, DE, Alexander, J, Nambiar, S, Hypersensitivity reactions associated with fidaxomicin use. Clin Infect Dis 58 (2014), 537–539.
16. Pichenot, M, Héquette-Ruz, R, Le Guern, R, et al. Fidaxomicin for treatment of Clostridium difficile infection in clinical practice: a prospective cohort study in a French University Hospital. Infection 45 (2017), 425–431.
17. Wilcox, MH, Gerding, DN, Poxton, IR, et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med 376 (2017), 305–317.
18. Chakra, CNA, Pepin, J, Sirard, S, Valiquette, L, Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review. PLoS One, 9, 2014, e98400.
19. Nathwani, D, Cornely, OA, Van Engen, AK, Odufowora-Sita, O, Retsa, P, Odeyemi, IA, Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection. J Antimicrob Chemother 69 (2014), 2901–2912.
20. Sclar, DA, Robison, LM, Oganov, AM, Schmidt, JM, Bowen, KA, Castillo, LV, Fidaxomicin for Clostridium difficile-associated diarrhoea: epidemiological method for estimation of warranted price. Clin Drug Investig 32 (2012), e17–e24.
21. Stevens, VW, Nelson, RE, Schwab-Daugherty, EM, et al. Comparative effectiveness of vancomycin and metronidazole for the prevention of recurrence and death in patients with Clostridium difficile infection. JAMA Intern Med 177 (2017), 546–553.
22. Nerandzic, MM, Mullane, K, Miller, MA, Babakhani, F, Donskey, CJ, Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin Infect Dis 55:suppl 2 (2012), S121–S126.
23. Olsen, MA, Yan, Y, Reske, KA, Zilberberg, MD, Dubberke, ER, Recurrent Clostridium difficile infection is associated with increased mortality. Clin Microbiol Infect 21 (2015), 164–170.
24. Sirbu, BD, Soriano, MM, Manzo, C, Lum, J, Gerding, DN, Johnson, S, Vancomycin taper and pulsed regimen with careful follow up for patients with recurrent Clostridium difficile infection. Clin Infect Dis 65 (2017), 1396–1399.
25. Crowther, GS, Chilton, CH, Longshaw, C, et al. Efficacy of vancomycin extended-dosing regimens for treatment of simulated Clostridium difficile infection within an in vitro human gut model. J Antimicrob Chemother 71 (2016), 986–991.